Harshad Amin, MD
Hematology & Oncology · Plantation, FLNPI 1679807242
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Lilly USA, LLC at 42.8% of the total. Reporting peaked in 2019 at $62,903 and has fallen 92.5% since, to $4,718 in 2025. Among hematology & oncology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,945 payments — averaging $81.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$68K
- Bristol Myers Squibb$15K
- Global Blood Therapeutics, Inc.$10K
- Bayer$8K
- Acceleron Pharma, Inc.$7K
- Jazz Pharmaceuticals Inc.$4K
- plus $46K from 54 others
Across 712 payments — averaging $5255.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Co., Ltd.$855K
- Pfizer$665K
- GSK$419K
- Karyopharm Therapeutics Inc.$355K
- Sanofi US Services Inc.$309K
- Eisai Inc.$267K
- plus $872K from 10 others
What the payments were for
- Consulting fees$43,55127%
- Speaking & faculty fees$69,95044%
- Travel & lodging$13,7349%
- Food & beverage$30,04519%
- Education$1,8451%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$159,125 in reported general payments places this provider in the 90th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 59 | $1,376,700 |
| Lenalidomide | 90 | $1,346,594 |
| RevlimidLenalidomide | 34 | $535,389 |
| TagrissoOsimertinib Mesylate | 31 | $518,214 |
| XpovioSelinexor | 13 | $435,513 |
| NubeqaDarolutamide | 26 | $390,834 |
| CabometyxCabozantinib S-Malate | 15 | $370,366 |
| InqoviDecitabine/Cedazuridine | 43 | $354,808 |
| LenvimaLenvatinib Mesylate | 14 | $354,015 |
| VenclextaVenetoclax | 23 | $318,512 |
| JakafiRuxolitinib Phosphate | 20 | $289,880 |
| VerzenioAbemaciclib | 18 | $284,852 |
| Abiraterone Acetate | 94 | $266,277 |
| TasignaNilotinib Hcl | 16 | $245,909 |
| IbrancePalbociclib | 15 | $245,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $2,754 | $1,376,70059 claims |
| Bristol Myers SquibbRevlimid | $15,177 | $535,38934 claims |
| AstraZenecaTagrisso | $3,367 | $518,21431 claims |
| Karyopharm Therapeutics Inc.Xpovio | $281 | $435,51313 claims |
| PfizerIbrance, Eliquis | $2,606 | $391,024193 claims |
| BayerNubeqa | $7,668 | $390,83426 claims |
| Exelixis Inc.Cabometyx | $3,946 | $370,36615 claims |
| Lilly USA, LLCVerzenio, Cyramza | $68,147 | $356,17134 claims |
| Taiho Oncology, Inc.Inqovi | $326 | $354,80843 claims |
| Eisai Inc.Lenvima | $1,033 | $354,01514 claims |
| AbbVieVenclexta | $622 | $318,51223 claims |
| Incyte CorporationJakafi | $888 | $289,88020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Plantation
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
- Vamsidhar VelchetiJacksonville$966K
- Shahram MoriOrlando$952K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.